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Abstract: The aquatic bioconcentration of a chemical is typically determined using conventional fish tests. To foster the
approach of alternatives to animal testing, a combination of computational models and in vitro substrate depletion bioassays
(e.g., primary hepatocytes) can be used. One recently developed in vitro assay is the three‐dimensional (3D) hepatic spheroid
model from rainbow trout (Oncorhynchus mykiss). The aim of the present study was to evaluate the metabolic competence of
the 3D spheroids from rainbow trout when exposed to pyrene, using 2 different sampling procedures (SP1 and SP2). The
results were compared with previously published intrinsic clearance (CL) results from S9 fractions and primary hepatocyte
assays. Extraction of pyrene using SP1 suggested that the spheroids had depleted 33% of the pyrene within 4 h of exposure,
reducing to 91% after 30 h. However, when applying SP2 a substantial amount (36%) of the pyrene was bound to the
exposure vial within 2 h, decreasing after 6 h of exposure. Formation of hydroxypyrene‐glucuronide (OH‐PYR‐Glu) was
obtained throughout the study, displaying the metabolic competence of the 3D spheroids. The 2 sampling procedures
yielded different CLin vitro, where pyrene depletion using SP2 was very similar to published studies using primary hepato-
cytes. The 3D spheroids demonstrated reproducibile, log‐linear biotransformation of pyrene and displayed formation of
OH‐PYR‐Glu, indicating their metabolic competence for 30 h or more. Environ Toxicol Chem 2019;38:1738–1747. © 2019
The Authors. Environmental Toxicology and Chemistry published by Wiley Periodicals, Inc. on behalf of SETAC.
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INTRODUCTION
Organic compounds in the aquatic environment are of con-
cern if they fulfill one or more of the criteria for being a persis-
tent, bioaccumulative, or toxic substance. Bioaccumulation of
hydrophobic organic compounds may occur in aquatic organ-
isms such as fish. The assessment of a compound’s potential to
bioconcentrate is currently based on its physicochemical prop-
erties (e.g., logKOW as a surrogate metric for the propensity of a
chemical to partition into the fats of fish) and subsequently its
biotransformation potential, using conventional animal test
methods such as fish (e.g., Organisation for Economic Co‐
operation and Development [OECD] Test Guideline 305). In vivo
testing gives rise to both ethical and economic concerns
because full bioconcentration studies use large numbers of ex-
perimental animals (e.g., 81 fish/study; Lillicrap et al. 2016b) and
require dedicated testing facilities. Alternatives to these test
methods have been requested (Schirmer 2006; Rovida and
Hartung 2009; Scholz et al. 2013; Lillicrap et al. 2016a). To ac-
commodate these requests, computational (in silico) nonanimal
models such as quantitative structure–activity relationships have
been used to assess a compound’s potential to bioconcentrate
in aquatic vertebrates (fish; Scholz et al. 2013). Unfortunately,
there are large knowledge gaps in some of these computational
predictive models because many chemical domains are not fully
covered by experimental information or are not able to account
for biotransformation (Arnot and Gobas 2006; Johanning et al.
2012). However, recent developments of computational models
have successfully predicted biotransformation rate constants for
several compounds in fish (Arnot et al. 2009; Papa et al. 2014),
although further refinement is still warranted.
In an effort to further improve the predictions of currently
existing computational models and endorse the refinement, re-
duction, and replacement (3Rs) of animal testing, a battery of well‐
established in vitro tests (e.g., S9 fractions, primary hepatocyte
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cells, and continuous cell lines) have been evaluated for their
applicability as alternatives to complement conventional in vivo
bioaccumulation models (Fay et al. 2014a, 2014b; Embry et al.
2015; Fay et al. 2017; Stadnicka‐Michalak et al. 2018). Recently,
OECD guidance documents concerning the use of in vitro assays
for extrapolation to in vivo intrinsic clearance were published
(OECD 2018). These OECD test guidelines (319A and 319B)
describe the use of S9 fractions and cryopreserved hepatocytes
from rainbow trout (Oncorhynchus mykiss). The test guidelines
were the result of an international ring trial (Nichols et al. 2018) that
tested a broad range of hydrophobic compounds including the
model compound pyrene. This polycyclic aromatic hydrocarbon
(PAH) is a nonpolar and nonionic compound with intermediate
hydrophobicity (logKOW 4.88) and is therefore a suitable model
compound to use in intrinsic clearance (CL) assays.
Identification of highly metabolically active hepatic in vitro
models accommodating biotransformation of PAHs (e.g.,
pyrene) as described in fish livers through phase I (mostly
oxidation) reactions forming 1‐hydroxypyrene (OH‐PYR) and its
further conjugation through phase II biotransformation (e.g.,
UDP‐glucuronosyltransferase or sulfotransferase; Van der Oost
et al. 2003) into 1‐hydroxypyrene‐glucuronide (OH‐PYR‐Glu)
and/or pyrene‐sulfate (Ikenaka et al. 2013) is highly warranted.
Such in vitro model is the three‐dimensional (3D) hepatic
spheroid culture that is well established in mammalian phar-
macology and cancer research because it has been suggested
to better reflect in vivo exposure and organ response than
monolayer cell cultures (Elliott and Yuan 2011; Kyffin et al. 2018).
The spheroid model has shown promise in prolonged duration
of exposure (>72 h; Hoffmann et al. 2015; Baron et al. 2017;
Ramaiahgari et al. 2017), enabling tests of slowly metabolizing
compounds that previously had been a challenge for well‐es-
tablished in vitro bioassays (e.g., S9 and primary hepatocytes)
because of their shorter shelf life (i.e., reduced viability over
extended durations). In addition, the spheroid model may better
reflect in vivo tissue activity and functionality because its mi-
croenvironment, cellular ultrastructure, metabolic competence,
and toxicity response is improved compared with 2D‐based
assays (Kyffin et al. 2019; Lammel et al. 2019). The 3D hepatic
spheroid model was not established in fish until recently, using
primary cells from rainbow trout that have successfully been
used in biotransformation studies of selected pharmaceuticals
(Baron et al. 2012; Baron et al. 2017). The 3D model has since
been developed for different cells of origin (primary cells and
continuous cell lines) in fish and has been used in investigation
of toxic effects and metabolism of xenobiotic compounds and
pharmaceuticals (Uchea et al. 2015; Langan et al. 2018; Lammel
et al. 2019). However there are very few studies, apart from
those involving pharmaceuticals, that have evaluated the ability
of 3D hepatic spheroids to metabolize environmentally relevant
organic compounds (Uchea et al. 2015).
The aim of the present study was to evaluate the bio-
transformation performance of 3D hepatic spheroid cultures
from rainbow trout, and to compare the results with other ex-
perimental in vitro models assessing biotransformation (such as
S9 fractions and primary hepatocytes from rainbow trout).
Pyrene was used as the test substance to characterize the
spheroid culture’s metabolic performance, and to determine its
possible applicability as an alternative in vitro model to assess
compounds’ biotransformation. To test the in vitro modelʼs
metabolic capacity, both parent pyrene and its transformation
products were measured at the end of the exposure period.
The measured transformation products were OH‐PYR and
OH‐PYR‐Glu. Moreover, the concentration of pyrene was
assessed throughout the exposure period in spheroid/media
and the test vessel because the intermediate logKOW may affect
the total amount of chemical in solution during the duration of
exposure. The spheroid’s biotransformation capacity was
thereafter compared with other in vitro biotransformation
models such as the S9 fractions and primary hepatocytes from
rainbow trout as reported in Organisation for Economic
Co‐operation and Development (2018).
MATERIALS AND METHODS
Test chemicals
The test chemical pyrene (purity 98%; CAS 129‐00‐0) was
purchased from Sigma‐Aldrich. Acetone (purity ≥ 99.9%; CAS
67‐64‐1) and acetonitrile (purity ≥ 99.95%; CAS 75‐05‐8) were
obtained from VWR. β‐glucuronidase/aryl sulfatase was purchased
from Merck. A concentrated stock solution of pyrene (5 mM) used
for the biotransformation assays was dissolved in acetone and
stored for a maximum of 2 wk in the dark at −20 °C before use.
Fish
Sexually immature rainbow trout (200–500 g) were obtained
from Valdres Ørretoppdrett and reared at the Department of
Biosciences at the University of Oslo for a minimum of 4 wk
before the start of the study. The fish were maintained in tap
water at 8 ± 2 °C, pH 6.6 at a regime of 12:12‐h, light:dark cycle.
Fish were fed daily with commercial pellets (Skretting) ad libitum.
3D spheroid cultivation
A total of 6 fish were collected (from September–November
2016) and humanely terminated with a blow to the head, fol-
lowed by immediate dissection to expose the abdominal cavity
and the lateral abdominal vein. Only immature fish with no
visually matured gonads were subjected to a 2‐step hepatic cell
isolation procedure by perfusion through the lateral abdominal
vein/hepatic portal vein, as previously described by Tollefsen
et al. (2003). Viability (>90%) of the isolated primary hepato-
cytes was assessed using a Bürker‐Türk counting chamber and
Trypan blue:cell suspension (2:1, v/v). The hepatocyte
suspension was diluted to 1 × 106 cells/mL in Leibovits 15 (L‐15)
media (with L‐glutamine, without phenol) supplemented with
sterile 10% foetal bovine serum, amphotericin (0.25 g/mL),
streptomycin (100 mg/mL), penicillin (100 U/mL), and NaHCO3
(4.5 mM). The cell suspension was seeded by dispensing 3 mL
into separate wells of a 6‐well plate pre‐coated with 2.5%
pHEMA to avoid any surface attachment, as earlier described
by Baron et al. (2012). The cell plates were thereafter placed on
an orbital shaker (Mini Shaker‐15; VWR) at 78 rpm and in-
cubated in an ambient atmosphere at 15 °C until the spheroids
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reached maturity (>8 d; Baron et al. 2012). Culture media was
changed within 24 h of cell isolation and thereafter 3 times per
wk. Preparation of pHEMA pre‐coated cell plates and all cell‐
related activities after cell isolation were carried out in a HEPA
filter (Class II) laminar flow sterile cabinet (Holten LaminAir
Model 1.5). The spheroids were evaluated by visual inspection
under a light microscope to ensure maturity was reached within
7 to 8 d, and were viable up to 37 d after seeding (Figure 1).
Preparation of spheroids for exposure
Once maturity was reached, 10‐ to 18‐d old spheroids with a
diameter between 90 to 150 µm were carefully collected using a
cut‐off pipette tip and dispensed into a sterile Falcon tube that
was centrifuged at 300 rpm for 3 min. The cell media was re-
moved using a pipette and replaced with 15‐mL L‐15 media
without any media supplements. Because the spheroids were
too large for a haemocytometer, they were morphologically as-
sessed and counted under a light microscope (×20) in 4 × 10‐µL
droplets. Once the spheroid concentrations were established,
preparations of 50 and 100 spheroids in 140 µL of media (357
and 714 spheroids per mL) were conducted. Aliquots of the
different densities of spheroid solutions were also heat‐
inactivated for 20 min at 100 °C and used as a parallel negative
enzymatic control for all the sample time points. Morphological
integrity and cell viability were continuously assessed (at 0, 2, 4,
6, 24, and 30 h) during the experiment.
Chemical exposure
The 5‐mM pyrene concentrated stock solution was diluted to
a 50‐µM pyrene stock solution using acetone on the experi-
mental start day, and further diluted to 50 nM (0.1% acetone) in
an intermediate stock that was added to the 3D spheroid solu-
tion, reaching a final concentration of 25 nM (0.05% acetone)
in L‐15 media without any additional supplements. An
independent experiment was performed to chemically verify any
loss of the total amount of pyrene in the intermediate stock
solution (50 nM pyrene) during the dilution step after 1 h of
incubation, using acetone, reverse osmosis water (RO‐H2O), and
L‐15 media as dilution buffers. To further investigate whether
pyrene was binding to the test vessel (glass vial) over the dura-
tion of exposure, an additional test was performed where
250 nM pyrene were spiked into an L‐15 solution containing 0.1
FIGURE 1: Light microscope images taken during aggregation of the rainbow trout (Oncorhynchus mykiss) hepatocytes and formation of spheroids
from 24 h up to 37 d.
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and 1% of bovine serum albumin (BSA) for a period of 0 to 6 h
because any chemical loss to the glass should occur within
that time.
Independent of previous experiments, the number of spher-
oids (50 or 100) and duration (0, 0.5, 1, 2, 4, 6, 24, and 30 h) of
exposure were evaluated by first dispensing a 140‐µL aliquot of
live and heat‐inactivated spheroids into 4× 1.5‐mL glass vials,
respectively, creating 4 technical replicates per exposure time. On
exposure, 140 µL of 50 nM pyrene solution were added to the
exposure vials, resulting in a final concentration of 25 nM pyrene
(0.05% acetone). The spheroids were exposed to 25 nM pyrene
for the duration of the exposure. The substrate depletion assay
was stopped at the individual time points by extracting one
individual replicate by adding 1200‐µL, ice‐cold acetonitrile
in a 1:5 ration of sample:acetonitrile (Organisation for Economic
Co‐operation and Development 2018).
To obtain optimal log‐linear depletion kinetics for the test
compound, an assessment of the best sampling strategy was
performed to measure compound biotransformation in the vial
containing 3D spheroids. The sampling procedure (SP1) was
carried out directly in the exposure vials as previously described
by Baron et al. (2017) and by moving the spheroids and exposure
media into a new vial (SP2). Sampling procedure 1 was conducted
to replicate 3D spheroid experiments performed by Baron et al.
(2017). Nevertheless, earlier studies (Qian et al. 2011) and che-
mical analysis indicated that there was likely to be a reduction in
the amount of pyrene present in the solution. Accordingly, SP2
was used to determine the total amount of pyrene in the cell
media (including spheroids) solution versus the identified amount
of pyrene adsorbed to the glass wall of the exposure vial. In short,
on stopping the metabolic reaction at each sampling point, all
media and spheroids were collected and dispensed into a new
vial followed by addition of 1200 µL acetonitrile. Correspondingly,
the exposure vial was extracted by adding 1480 µL of acetonitrile
to obtain any analyte adhered to the glass vial.
Protein analysis
Protein was analyzed in samples containing BSA using the
modified Lowry method (Lowry et al. 1951). In summary, 10 µL of
sample and bovine ɤ‐globulin protein standard (0.125–1.125
mg/mL diluted in 0.1 M Tris buffer; pH 8.0) were pipetted into a
96‐well plate followed by addition of 25 µL of alkaline copper
tartrate solution (Bio‐Rad) and 200 µL of Folin’s reagent (Bio‐
Rad). The plate was gently mixed and then incubated for 15 min
in the dark at room temperature (20 °C). The plate was read at
750‐nm absorbance on a VersaMax 96‐well microplate reader
(Molecular Devices).
Chemical analysis
Chemical analyses of pyrene and its transformation products
were performed using a Waters 2695 high‐performance liquid
chromatography (HPLC) Separations Module attached to a
2475 fluorescence detector. A Waters PAH C18 column
(4.6 × 250 mm) with 5‐μm particles was used. The mobile phase
consisted of a gradient from 40:60 acetonitrile:ammonium
acetate (0.05 M; pH 4.1) to 100% acetonitrile at a flow of
1 mL/min. The column was heated to 35 °C. Fluorescence was
measured at the following excitation/emission wavelengths:
1‐hydroxypyrene β‐D‐glucuronide 342/380 nm; OH‐PYR, and
pyrene 346/384 nm. Aliquots of 25‐μL samples were injected
directly into the HPLC for each analysis. The results were cal-
culated using the external standard method. The calibration
standards were obtained from Chiron and were in the range of
0.1 to 10 ng/mL. The procedure was described in detail in
Kammann et al. (2013) and showed good results (z score<1) for
quantification of OH‐PYR in an interlaboratory ring trial.
Deconjugation using β‐glucuronidase/aryl sulfatase enzyme was
performed in several samples to show that OH‐PYR was formed
during the exposure duration, as previously described in Kam-
mann et al. (2013). β‐glucuronidase/aryl sulfatase enzyme was
added in a 1:10 ratio (enzyme:sample), mixed thoroughly, and
incubated at 37 °C for 1 h before injection. The analytical ap-
proach used herein was developed for pyrene and not
specifically for the analysis of metabolites OH‐PYR and OH‐PYR‐
Glu. Analytical uncertainty associated with the low levels of
metabolites observed therefore prevented an appropriate
accurate mass‐balance calculation.
Determination of in vitro and in vivo hepatic
intrinsic CL
The intrinsic CL rate of the spheroids (CLin vitro, spheroid; mL/h/10
6
cells) was determined for pyrene using a substrate depletion ap-
proach. Measured substrate concentrations of pyrene were log10‐
transformed and plotted against time (h) to obtain a first‐order
elimination rate constant (k= –2.3× slope; Remington 2006). The
CLin vitro, spheroid was determined by dividing the elimination rate
constant by total cell number, approximated as 500 cells/spheroid
and thus 5.0× 104 cells in 100 spheroids per well (Baron et al.
2012). To estimate the in vivo intrinsic CL rate
(CLin vivo, spheroid; mL/h/g liver) the CLin vitro, spheroid value was
multiplied by the hepatocellularity value identified as 5.1× 108
hepatocytes/g liver for sexually immature rainbow trout
(Fay et al. 2014a).
Statistical analysis
Statistical analysis was performed on the initial experiment
measuring pyrene concentration in the intermediate stock
solutions to identify any significant (p< 0.05) difference in dis-
solved pyrene concentration in acetone, L‐15, and RO‐H2O.
The analysis was performed using GraphPad Prism Ver 5.04
(GraphPad Software) applying analysis of variance with Tukey’s
post hoc test after the criteria for homogeneity were met.
RESULTS
Chemical analysis
The chemical analysis quantified pyrene (retention time [Rt]
23.1 min), OH‐PYR‐Glu (Rt 4.2 min), and an unknown pyrene
metabolite (Rt 4.8 min) in the exposure media. The unidentified
pyrene metabolite appeared as a defined peak in the
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chromatogram in some samples, and the levels increased with
the duration of exposure. Surprisingly, there was no measur-
able detection of OH‐PYR (Rt 14.1 min) in any of the analyzed
samples. However, when performing a deconjugation of
the metabolites by β‐glucuronidase/aryl sulfatase, a time‐
dependent (1–30 h) increase of the OH‐PYR was detected,
displaying measurable levels during the whole duration of
exposure (data not shown).
To fully assess the study design and identify any potential loss
of compound, analytical chemistry was performed in all dilution
steps before exposure. Three different media (acetone, L‐15,
and RO‐H2O) were tested, assessing the total amount of pyrene
present in the solution and adsorbed (not bioavailable) to the
glass bottle after 1 h of incubation. There was a slight loss of
dissolved compound (50 nM) during the intermediate dilution
step, identifying a significant difference (p< 0.05) in total
amount of pyrene in solution between acetone and RO‐H2O.
Despite this difference, both solutions were within the nominal
concentration of 50 nM and the amount of dissolved pyrene was
therefore not considered to be affected by the media into which
it was spiked when used within 1 h of preparation.
The presence of 0.1 and 1% of BSA in the pyrene solution
marginally increased the total amount of dissolved pyrene
concentration in the media (0–2 h), with 1% BSA having
the highest retention capacity after 2 h of incubation
(Supplemental Data, Figure S1).
Evaluation of the number of spheroids and
exposure duration
The different number of spheroids and exposure periods
were both assessed with the aim of ensuring log‐linear deple-
tion kinetics for pyrene. It was established that 100 spheroids
per reaction primarily had higher replicate reproducibility and
were therefore used throughout the study. In addition, the
elimination rate (k = –0.050) was higher compared with 50
spheroids (k = –0.010) during 0 to 6 h of exposure to pyrene
(Supplemental Data, Figure S2). It was thus decided that 100
spheroids per reaction were sufficient to yield reproducible
depletion kinetics of pyrene (coefficient of variation 1.7–13%) in
addition to displaying its biotransformation efficiency by for-
mation of OH‐PYR‐Glu (Supplemental Data, Figure S2). All
studies thereafter were performed under conditions that
resulted in log‐linear depletion kinetics of pyrene.
In the preliminary experiments, the exposure time of 6 h was
determined to not be of sufficient duration because 50% or
higher depletion of the original pyrene concentration (thalf‐life >
6 h) was thought to yield more reproducible results when
conducting multiple cell batch experiments (Supplemental
Data, Figure S2). The duration of exposure was therefore pro-
longed to 30 h, resulting in both representative depletion (t30 h
91%) and a reproducible log‐linear metabolic rate of pyrene
(Figure 2). There was formation of OH‐PYR‐Glu during the full
duration of pyrene exposure (0–30 h), indicating continuous
biotransformation of pyrene (Supplemental Data, Figure S3).
Heat‐inactivated spheroids were used as a negative control for
biotransformation and did not display any biotransformation of
pyrene during the full duration of exposure (Figure 2). Cell
viability was assessed between 0 through 30 h of exposure
duration and ranged from 49 to 78% compared with a parallel
untreated control at the end of the experiment (30 h)
represented by one technical replicate. This decrease in cell
viability suggested that the pyrene concentration may have had
a cytotoxic effect on the spheroids; nevertheless, in the present
study the spheroids appeared to have retained their metabolic
competence throughout the 30 h of exposure because 93 to
96% of the initially spiked‐in pyrene was metabolized at the
end of the exposure period.
Evaluation of sampling procedure to obtain
intrinsic CL
Because the chemical analysis revealed a reduction of dis-
solved pyrene in the media and spheroid solution not related to
the spheroids’ biotransformation in SP1, both SP1 and SP2 were
applied. Sampling procedure 1 was carried out according to
Baron et al. (2017) with some modification, stopping the meta-
bolic activity of the spheroids directly in the exposure vial. This
approach involved spiking cold acetonitrile directly into the ex-
posure vessel and provided a measure of the total amount of
analyte(s) in the system either bound within the spheroids or to
media constituents, freely dissolved in the media, or bound to
the glass exposure vessel. In sampling procedure 2, the media
and spheroids were transferred from the exposure vessel and
spiked directly into a volume of cold acetonitrile. This process
was done to make the design of the 3D spheroid study more
comparable with earlier compound depletion studies utilizing
primary hepatocytes and S9 fractions (Fay et al. 2014b; Fay et al.
2017; Nichols et al. 2018). Sampling procedure 2 provided only
a measure of the amount of analyte within the spheroid bound
to media constituents and dissolved in the media. Hence it did
not cover the proportion of the analyte(s) that might have been
bound to the surface of the exposure vessel.
Figure 2 details the results of SP1, whereas Figure 3 shows
the kinetics of SP2. Sampling procedure 1 disclosed first‐order
FIGURE 2: Assessment of optimal exposure time to determine sub-
strate depletion kinetics of 25 nM pyrene (PYR). The graph displays the
clearance of pyrene (■) in alive and heat‐inactivated (○) 3D spheroids.
The data represent the mean (±standard error) of 3–4 technical
replicates consisting of 100 spheroids each collected from one fish.
k = rate constant.
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kinetics throughout the duration of the exposure (0–30 h). The
spheroids depleted 33% of the original spiked pyrene within
4 h of exposure, further metabolizing a total of 50, 85, and 91%
after 6, 24, and 30 h, respectively (Figure 2). Sampling proce-
dure 2, on the other hand, showed an apparent change in the
kinetics over time, clearly not being at equilibrium until after 6 h
of exposure to pyrene (Figure 3). There was a steep depletion
of the total amount of pyrene in the media + spheroid between
0 to 4 h followed by an increase again after 6 h of exposure,
representing a depletion of 82 and 84% within the first 2 and
4 h of exposure, respectively (Figure 3). However, in analyzing
the pyrene adhered to the glass vial, 36% of the originally
added pyrene was adsorbed to the glass wall within 2 h of
exposure. Correcting for the pyrene adhered to the glass, the
calculated depletion of pyrene by the 3D spheroids was 46 and
58% of the originally spiked‐in compound after 2 and 4 h,
respectively. The total amount of pyrene in the spheroid +
media compartment was, after 6 h of exposure, depleted in a
log‐linear manner until the end of the exposure (30 h). The
pyrene continued to be adsorbed to the glass at quantities of
33 and 2% for the duration of 6 and 24 h, respectively
(Supplemental Data, Figure S4). However, based on the
depletion rate of pyrene adhered to the glass, this was not a
rate‐limiting factor for metabolism of pyrene by the spheroids.
Similarly, OH‐PYR‐Glu also had a high affinity for the glass
wall of the vessel during the full duration of the test (Supple-
mental Data, Figure S4). Heat‐inactivated spheroids displayed
a decrease in pyrene concentration over time when combining
the 2 compartments (spheroids + media and vial (Figure 3)).
Nonetheless, this reduction of pyrene was inconsistent over
time and because it previously showed not to be an artefact
(Figure 2), it was regarded as a confounding factor associated
with the chemical analysis and/or recovery of all compound in
the different compartments during SP2.
Overall, the intercell batch variation of biotransformation
efficiency (regardless of sampling procedure) varied between
16 to 48% coefficient of variation during the 30‐h exposure,
and was the least variable at 2 h of exposure (16%). The 2
different sampling procedures did however yield similar elim-
ination rates for pyrene when analyzing the whole exposure vial
(k = –0.034) versus the spheroid + media (k = –0.042). How-
ever, to be comparable with previous in vitro work on pyrene
depletion, the elimination rate of total amount of pyrene in
measured spheroid + media was used to calculate the intrinsic
CL of pyrene in 3D spheroids.
Calculation of intrinsic CL of spheroids
(CLin vitro, spheroid) and extrapolation to
in vivo (CLin vivo, spheroid)
The in vitro intrinsic CL rate of pyrene by 3D spheroids was
very similar to previously published studies using cryopreserved
hepatocytes (Table 1). Similarities between the 3D spheroids and
cryopreserved hepatocytes were also evident when extrapolating
the results to estimates of in vivo intrinsic CL. Comparisons be-
tween 3D spheroids and S9 fractions, however, showed larger
differences in estimated in vivo intrinsic CL (Table 1).
DISCUSSION
The primary objective of the present study was to evaluate
the performance and reproducibility of an in vitro substrate
depletion assay using a 3D rainbow trout hepatic spheroid
model. To the knowledge of the authors, there have been no
previous studies that investigated the 3D spheroid model’s
biotransformation capacity of pyrene and the formation of the
presumed metabolites OH‐PYR and OH‐PYR‐Glu.
Experimental data to evaluate the suitable number of
spheroids and the duration of exposure suggested that 100
spheroids per reaction and an exposure duration of 30 h yielded
the most reproducible data. This was consistent with a pre-
viously published study by Baron et al. (2017). However, during
the investigation of the suitable number of spheroids there were
differences between the clearance rate constant (k) obtained
from 50 and 100 spheroids (Supplemental Data, Figure S2). As a
result of a lack of information in the literature, it is not possible to
determine why this is occurring. The authors suggest there could
be at least 2 explanations: 1) there was not an excess of bio-
transformation enzyme in the spheroid system, a hypothesis that
might be verified if a plateau was observed in k after experi-
ments with increasing numbers of spheroids (e.g., 150, 200, 250,
etc.), and/or 2) there was an excess of biotransformation enzyme
even at the reaction using 50 spheroids but the rate was limited
by another factor such as available surface area or other factors
associated with the spheroid microenvironment. Langan et al.
(2018) recently proposed that spheroid size is a possible con-
tributing factor to lower metabolism of the test compound be-
cause of an effect on the internal oxygen diffusion into the inner
layer of larger (>400 µm) as compared with smaller (<200 µm)
spheroids. To ensure that the spheroids’ viability and basic
cellular activity were not limited by their microenvironment
(e.g., anoxia in the center of the spheroid), spheroid sizes of 90
to 150 µm in diameter were used in all experiments conducted.
This suggests that oxygen consumption was probably not the
determining factor affecting the metabolism/clearance rate of
FIGURE 3: Evaluation of biotransformation of 25 nM pyrene (PYR)
during 30 h of exposure when separating spheroids (sph) +media from
the exposure vial before stopping the reaction. The graph denotes the
clearance of pyrene when separately stopping the reaction in spher-
oids + media (■). Heat‐inactivated 3D spheroids (○) are calculated for
the whole vial. The data represents the mean (±standard error) of 2
independent assays, each consisting of 100 spheroids per 3‐4 technical
replicate. k = rate constant.
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pyrene in the present study. Apart from a potential impact by
the oxygen‐regulated microenvironment, the size‐dependent
metabolic rate might also be caused by the lower surface area
(compared with smaller spheroids and ultimately single cells) in
addition to the lag time for the compound to reach the bio-
transformation site. Another factor that might affect the clear-
ance rate is the bioavailability of the compound that might be
dependent on the amount of protein present in the 50‐ and
100‐spheroid sample solution. To address this, the present study
tested the retention capacity of pyrene in L‐15 by using different
BSA concentrations. It was found that protein content of 1% BSA
had a slightly higher capacity of keeping the amount of spiked‐in
pyrene stable over time in the L‐15 media compared with 0.1%
BSA (Supplemental Data, Figure S1). Nevertheless, further re-
search would be required to reach a definitive conclusion as to
why this difference in clearance rate is occurring. Until then, it
cannot be concluded that the chosen number of spheroids (100
spheroids per reaction) yielded the optimal depletion rate of
pyrene during the 30 h of testing. Consequently, to make this
bioassay feasible and possibly applicable as a future compound
biotransformation method, the lowest number of spheroids
yielding the most reproducible data was used.
To obtain high biotransformation efficiency, only mature
spheroids (>8 d post‐isolation) were used in the present study
(ages 10–18 d post‐isolation) because they have been shown to
have an increased activity of proteins associated with meta-
bolite excretion through the cellular efflux transporters (e.g.,
proteins of the adenosine triphosphate‐binding cassette; Xu
et al. 2005; Uchea et al. 2015), compared with immature (5–7 d
post‐isolation) hepatic spheroid cultures of trout (Uchea et al.
2015). The selected 3D spheroids demonstrated high meta-
bolic activity with measurable depletion of pyrene after only 2 h
of exposure, displaying a log‐linear depletion up to 30 h of
exposure. Biotransformation of pyrene had previously been
expected based on the continuous compound clearance in in
vitro substrate depletion assays such as primary hepatocyte
and S9 fractions (Nichols et al. 2018); however, analytical ver-
ification of, for example, formation of metabolites has been
warranted. In the present study, we confirmed analytically that
pyrene was taken up and biotransformed into the metabolite
OH‐PYR‐Glu by the hepatic spheroids. The 3D spheroids ex-
hibited a continuous formation of OH‐PYR‐Glu until 30 h of
exposure to pyrene. The quantification of OH‐PYR‐Glu was,
nevertheless, quite uncertain because of the short retention
time used in the present analytical method, although the time‐
dependent increase identified the metabolic activity of the
spheroids. Surprisingly, there was no detection of the phase I
metabolite OH‐PYR in any of the samples. To address this, a
deconjugation procedure of β‐glucuronidase/aryl sulfatase was
applied to identify the possible metabolites formed during the
pyrene exposure. This deconjugation procedure identified and
verified that there was a formation of OH‐PYR increasing over
the full duration of exposure. However, the lack of identification
in nondeconjugated samples suggests that the subcellular
conjugation process converting OH‐PYR into OH‐PYR‐Glu is
rapid enough that levels of OH‐PYR are below the limit of
analytical quantification (Saengtienchai et al. 2015). This isTA
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further supported by the fact that the majority of the metabo-
lites found in the hepatic spheroid samples were OH‐PYR‐Glu,
which together with pyrene sulphate are the 2 major conjuga-
tion metabolites expected in in vivo fish liver (Ikenaka et al.
2013). Pyrene sulphate was not specifically analyzed in the
present study but the chemical analysis highlighted an uni-
dentified pyrene metabolite peak on the chromatogram. This
peak was possibly OH‐PYR sulphate because the retention time
was longer (4.8 min) compared with the glucuronide
(4.2 min), which corresponds well with previous literature in
both fish and rats (Ikenaka et al. 2013; Saengtienchai et al.
2015). Our results revealed the 3D spheroids’ ability to bio-
transform pyrene into both phase I OH‐PYR and phase II
glucuronide and possibly sulphate metabolites, as previously
described for in vivo pyrene‐exposed fish (Ikenaka et al. 2013).
However, because we did not specifically investigate pyrene
sulphate, this conclusion remains to be confirmed.
Calculation of in vitro intrinsic clearance (CLin vitro) for the 3D
spheroids reported very similar values to the recently published
data for cryopreserved hepatocytes (Nichols et al. 2018; Organi-
sation for Economic Co‐operation and Development 2018).
Established in vitro intrinsic CL assays using S9 fractions and
primary hepatocytes (fresh and cryopreserved) have displayed
reproducible elimination rates within 14 and 50 min, when in-
cubated with 25 nM pyrene. The hepatic 3D spheroids require a
longer duration of exposure (30 h) to biotransform pyrene into its
metabolites OH‐PYR and OH‐PYR‐Glu, as shown both by the
present study and an earlier study (Baron et al. 2017). Similar
to spheroids, single cells (e.g., hepatocytes) have been re-
commended to require a prolonged duration of exposure
compared with S9 fractions because of co‐factor limitations and/or
rate‐limiting cell permeability (Fay et al. 2017). The larger size
(Ø 90–150 µm) and lower total surface area of the spheroids
compared with single hepatocytes (Ø 16.7 ± 0.4 µm; Moutou et al.
1997) may also be a reason for lower clearance rate of pyrene in
spheroids, although this is still to be experimentally verified.
Despite this, the advantage of using spheroid cultures compared
with subcellular (S9 fraction) assays is that the former better re-
present the in vivo system because the compound needs to be
transported across cell membranes (Uchea et al. 2015). This feature
is lacking in currently used S9 fraction substrate depletion assays,
where elimination is expected (Johanning et al. 2012). Bio-
transformation of slowly metabolized compounds (e.g., methoxy-
chlor) has proven challenging for both the S9 fractions and the
primary hepatocyte bioassay because depletion rates are close to
the lower limit of measurable chemical quantification (Nichols et al.
2018). This is yet another advantage of the hepatic rainbow trout
spheroids because the bioassay is viable for a prolonged exposure
duration (≥72 h; Baron et al. 2017), thus making them applicable for
testing of more challenging (e.g., highly hydrophobic, persistent)
compounds. However, the lowest limit of CLin vitro rate is still to be
experimentally established for all the in vitro depletion bioassays
(primary hepatocytes, S9 fractions, and the 3D spheroids).
The metabolic competence of spheroids used in the present
study is comparable with previous in vitro studies using cryo-
preserved hepatocytes (Table 1). There was however a differ-
ence in biotransformation of pyrene between the present study
and previous studies for both fresh and cryopreserved primary
hepatocytes incubated with 25 and 250 nM pyrene (Fay et al.
2017; Nichols et al. 2018). The recently published ring trial
study reported that cryopreserved hepatocytes yielded a factor
of 1.8 times higher CLin vitro than the present study (Nichols
et al. 2018). The same study estimated CLin vivo for S9 fractions
(2603 mL/h/g liver) to be 2.6 times higher than the hepatocyte‐
based assays. This suggests that the S9 fraction is more effi-
cient than the cryopreserved hepatocyte (Nichols et al. 2018)
and the spheroid‐based assays presented herein.
The interbatch variability was fairly high in the present study
(coefficient of variation 18–58%) but comparable with other stu-
dies reporting intercell batch variations of 30 to 50% when using
cryopreserved primary hepatocytes in metabolic clearance rate
assays (Mingoia et al. 2010). Nevertheless, when compared with
recent pyrene depletion studies using cryopreserved hepatocytes
(coefficient of variation 27.9± 11.0%; Nichols et al. 2018) the
present study had a higher coefficient of variation percentage.
Some of the variability may be attributed to the different cell
batches used and minor differences in the number of spheroids
per replicate, in addition to uncertainties in the analytical quan-
tification of low concentrations of pyrene. One explanation for the
low intralaboratory and interlaboratory variability reported by
Nichols et al. (2018) may be that the study was using a more
homogenous sample of hepatocytes as each mixed batch con-
sisted of 7 animals of different gender, yielding a possibly more
representative response than when testing individual cell batches.
In addition, previously described in vitro depletion assays (cryo-
preserved and S9 fraction) consisted of technical replicates that
were subsampled from one sample over time to establish the
compounds’ specific elimination rate (Fay et al. 2017; Nichols
et al. 2018; Organisation for Economic Co‐operation and Devel-
opment 2018). The present study did not perform subsamples
but instead sampled up to 4 technical replicates per time point,
which probably contributed to most of the variability observed.
Other features that might give rise to differences among
experimental studies using chemical depletion bioassays might
result from the sampling method. Herein, the application of the
2 different sampling procedures displayed similar elimination
rates during the test (Figures 2 and 3). However, SP1 was not
able to distinguish between adsorbed and dissolved pyrene
(free, bound‐to‐media constituents, and within spheroid) in the
test system (Figure 2). Despite the substantial amount of pyrene
adhering to the glass vial and thus being less available for
the spheroids, this was not the rate‐limiting factor for
metabolism of pyrene (Figure 3 and Supplemental Data,
Figure S4). Other studies using cryopreserved primary hepato-
cytes (Nichols et al. 2018) have not reported issues with
recovery of dissolved pyrene during their exposures. This might
be caused by the presence of higher dissolved protein content
(hepatocytes 2.85 ± 0.34 mg/mL; Nichols et al. 2018) in the
exposure vial than in the present study (spheroids 0.0211
mg/mL; calculations based on Baron et al. 2012). This was further
investigated in the present study by measuring total amount of
pyrene in the media in the presence of a protein content similar
to that reported for hepatocytes by Nichols et al. (2018; BSA
0.1%, 2.65 mg/mL). The data showed that homogenously
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dissolved BSA 0.1% had a 1.4 to 1.7 times higher retention of
the pyrene in solution than in L‐15 alone during 6 h of exposure.
These results display the potential challenges of using 3D
spheroids when testing highly hydrophobic compounds
because substantial amounts may be less available for the
spheroids (as a result of fewer and densely accumulated cells)
during the whole duration of the test. Pyrene is a small molecule
with only an intermediate hydrophobicity, and thus does not
pose the same challenges as larger and more hydrophobic
compounds. An example of such a compound would be meth-
oxychlor, which has been shown to have limited membrane
permeability that influences biotransformation inside cells
(Dimitrov et al. 2003; Johanning et al. 2012).
In summary, the present study illustrated the importance of
verifying the test compound’s bioavailability during the whole
test to account for how much of the test compound is available
to the spheroids. Many studies based on the metabolic clear-
ance assume that all spiked chemical is bioavailable for the cells
during the full duration of the test (Mingoia et al. 2010; Fay et al.
2014a, 2014b; Fay et al. 2017; Nichols et al. 2018). Although this
is not an issue for pyrene, slowly metabolized substances that
might have proven difficult to assess with S9 fractions and freshly
prepared hepatocytes requiring longer exposure durations be-
fore biotransformation might be better assessed using 3D
spheroids because they can be exposed for a longer period of
time (>72 h) and are viable for >30 d. Whereas recognizing that
further development of this assay requires additional
compounds to be assayed and interlaboratory ring trials to be
performed, at this time 3D spheroids could be considered
complementary to the other in vitro depletion assays. Ultimately,
its use in a weight‐of‐evidence approach such as the tiered
assessment strategy to improve bioaccumulation assessments of
chemicals recommended by Lillicrap et al. (2016b) is warranted.
CONCLUSIONS
The present study determined that 3D hepatic spheroids
from rainbow trout are highly metabolically active because they
biotransformed pyrene during 30 h of exposure at an intrinsic
CL rate comparable with other in vitro depletion assays. In
addition, the 3D spheroids displayed efficient biotransforma-
tion of pyrene into one of its metabolites (OH‐PYR‐Glu) during
the full duration of exposure. Compared with other in vitro
depletion assays, a major benefit of using 3D spheroids is that
their microenvironment is more similar to the in vivo tissue.
Moreover, 3D spheroids permit considerably longer exposure
durations. The present study suggested that the 3D spheroid
model might contribute valuable data that also might improve
the prediction of a compound’s bioconcentration potential in
vitro, and further extrapolation into in vivo.
Supplemental Data—The Supplemental Data are available on
the Wiley Online Library at DOI: 10.1002/etc.4476.
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